Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Andreas Josefsson
With
Umeå University
Sahlgrenska University Hospital
University Hospital, Umeå
Uppsala University Hospital
Skane University Hospital
Jonkoping County Hospital
Sundsvall Hospital
Helsingborgs Hospital
Göteborg University
Astellas Pharma Europe Ltd.
Norrlands University Hospital
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Positive COVID-19 test
Mild to severe symptoms of COVID-19
Hospitalization
WHO performance status 0-3
Age above or equal to 50 years
Can understand all the requirements of the study, provide informed consent, and provide authorization of use and disclosure of personal health information.
Estimated expected survival of 1 year (excluding symptoms due to COVID-19)
You may not be if
Severe allergy to Enzalutamide
Pregnant or breast-feeding women
Need of immediate mechanical ventilation
Current medication includes enzalutamide treatment
Stroke or Transitory Ischemic attack in medical history
Treatment for HIV
Treatment with tamoxifen
Treatment with immunosuppressive agents
Severe immunosuppressive disease
Treatment with warfarin or NOAC (Non-vitamin K-antagonist anticoagulants)
